Notes

Slide Show

Outline

1
2	Forward-looking Statements
3
4	Inventing New Medicines Breakthrough Treatments for Human Disease
5	Knockout Mouse Technology Recognized by 2007 Nobel Prize in Medicine
6
7	The 10_TO10 Pipeline: Advancing New Mechanisms Preclinical
8	LX2931: A New Drug Candidate for Rheumatoid Arthritis Autoimmune diseases result from a dysfunction of the immune system Inappropriate activation of lymphocytes, a type of white blood cell, is associated with autoimmune disease The immune system attacks the body’s own organs, tissues and cells Significant market* Rheumatoid arthritis affects 2.1 million Americans
9
10	LX2931 Reproduces S1P Lyase Knockout Phenotype: Decreased Peripheral Lymphocytes
11
12
13	LX2931 Shows Positive Results in Phase 1 Clinical Trial
14	Dose Dependent Reduction in Lymphocyte Counts Observed after Single Dose of LX2931in Phase 1 Trial
15	Rapid Reduction of Blood Lymphocytes Followed by a Return to Baseline in 96 hours after Single Dose
16	10_TO10: Innovative Drugs with New Mechanisms Completed initial regulatory filings for four new molecular entities LX6171 for cognitive disorders Phase 2 trial initiated November 2007 LX1031 for irritable bowel syndrome Phase 1b trial completed October 2007 LX2931 for rheumatoid arthritis Phase 1 trial initiated December 2007 LX1032 for carcinoid syndrome Phase 1 trial initiated February 2008
17	Lexicon Licensing Process
18
19